- Home
- ENVB vs KTTA Comparison
ENVB vs KTTA Comparison
Compare ENVB & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- KTTA
- Stock Information
- Founded
- ENVB 1994
- KTTA 2020
- Country
- ENVB United States
- KTTA United States
- Employees
- ENVB N/A
- KTTA N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- ENVB Health Care
- KTTA Health Care
- Exchange
- ENVB Nasdaq
- KTTA Nasdaq
- Market Cap
- ENVB 3.1M
- KTTA 2.8M
- IPO Year
- ENVB N/A
- KTTA 2021
- Fundamental
- Price
- ENVB $1.23
- KTTA $0.73
- Analyst Decision
- ENVB Strong Buy
- KTTA
- Analyst Count
- ENVB 1
- KTTA 0
- Target Price
- ENVB $10.00
- KTTA N/A
- AVG Volume (30 Days)
- ENVB 180.1K
- KTTA 201.2K
- Earning Date
- ENVB 08-11-2025
- KTTA 08-12-2025
- Dividend Yield
- ENVB N/A
- KTTA N/A
- EPS Growth
- ENVB N/A
- KTTA N/A
- EPS
- ENVB N/A
- KTTA N/A
- Revenue
- ENVB N/A
- KTTA N/A
- Revenue This Year
- ENVB N/A
- KTTA N/A
- Revenue Next Year
- ENVB N/A
- KTTA N/A
- P/E Ratio
- ENVB N/A
- KTTA N/A
- Revenue Growth
- ENVB N/A
- KTTA N/A
- 52 Week Low
- ENVB $1.01
- KTTA $0.70
- 52 Week High
- ENVB $11.55
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- ENVB 43.28
- KTTA 35.89
- Support Level
- ENVB $1.19
- KTTA $0.70
- Resistance Level
- ENVB $1.32
- KTTA $0.76
- Average True Range (ATR)
- ENVB 0.07
- KTTA 0.04
- MACD
- ENVB 0.01
- KTTA 0.01
- Stochastic Oscillator
- ENVB 29.41
- KTTA 16.63
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).